MA49522A - Nouveaux composés de quinoléinone - Google Patents
Nouveaux composés de quinoléinoneInfo
- Publication number
- MA49522A MA49522A MA049522A MA49522A MA49522A MA 49522 A MA49522 A MA 49522A MA 049522 A MA049522 A MA 049522A MA 49522 A MA49522 A MA 49522A MA 49522 A MA49522 A MA 49522A
- Authority
- MA
- Morocco
- Prior art keywords
- quinoleinone
- compounds
- new
- quinoleinone compounds
- new quinoleinone
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017090267 | 2017-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49522A true MA49522A (fr) | 2020-05-06 |
Family
ID=64741140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049522A MA49522A (fr) | 2017-06-27 | 2018-06-26 | Nouveaux composés de quinoléinone |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11384075B2 (fr) |
| EP (1) | EP3645526B1 (fr) |
| JP (1) | JP7261752B2 (fr) |
| KR (1) | KR20200020888A (fr) |
| CN (1) | CN111032643B (fr) |
| AU (1) | AU2018291687B2 (fr) |
| BR (1) | BR112019027676A2 (fr) |
| CA (1) | CA3068081A1 (fr) |
| ES (1) | ES2996878T3 (fr) |
| MA (1) | MA49522A (fr) |
| MX (1) | MX2020000135A (fr) |
| WO (1) | WO2019001419A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3123699A1 (fr) | 2018-12-26 | 2020-07-02 | Janssen Pharmaceutica Nv | Composes de thienopyridinone |
| JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
| JP2023511201A (ja) * | 2020-01-24 | 2023-03-16 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物的に活性な縮合二環式芳香族複素環式化合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| WO1998004689A1 (fr) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate |
| US20030028018A1 (en) * | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
| PL211125B1 (pl) | 2000-09-11 | 2012-04-30 | Novartis Vaccines & Diagnostic | Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie |
| FR2833948B1 (fr) | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament |
| CN100526312C (zh) | 2002-08-23 | 2009-08-12 | 诺华疫苗和诊断公司 | 苯并咪唑喹啉酮及其应用 |
| KR20050037585A (ko) | 2002-08-23 | 2005-04-22 | 카이론 코포레이션 | 벤지미다졸 퀴놀리논 및 그들의 사용 |
| CA2501932C (fr) | 2002-11-13 | 2014-03-11 | Chiron Corporation | Utilisation des quinolinones de benzimidazole pour le traitement du cancer |
| WO2004087153A2 (fr) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Utilisation de petites molecules de composes pour une immunopotentialisation |
| KR101224410B1 (ko) | 2003-11-07 | 2013-01-23 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 퀴놀리논 화합물을 합성하는 방법 |
| AU2005216904B2 (en) | 2004-02-20 | 2010-11-25 | Novartis Vaccines And Diagnostics, Inc. | Modulation of inflammatory and metastatic processes |
| EP1904480A2 (fr) | 2005-05-23 | 2008-04-02 | Novartis Pharma AG | Formes cristalline et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one |
-
2018
- 2018-06-26 EP EP18824291.1A patent/EP3645526B1/fr active Active
- 2018-06-26 CN CN201880055431.4A patent/CN111032643B/zh active Active
- 2018-06-26 MA MA049522A patent/MA49522A/fr unknown
- 2018-06-26 JP JP2019571951A patent/JP7261752B2/ja active Active
- 2018-06-26 ES ES18824291T patent/ES2996878T3/es active Active
- 2018-06-26 KR KR1020207002134A patent/KR20200020888A/ko active Pending
- 2018-06-26 WO PCT/CN2018/092830 patent/WO2019001419A1/fr not_active Ceased
- 2018-06-26 CA CA3068081A patent/CA3068081A1/fr active Pending
- 2018-06-26 BR BR112019027676-9A patent/BR112019027676A2/pt active Search and Examination
- 2018-06-26 MX MX2020000135A patent/MX2020000135A/es unknown
- 2018-06-26 AU AU2018291687A patent/AU2018291687B2/en active Active
- 2018-06-26 US US16/623,011 patent/US11384075B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111032643B (zh) | 2023-05-30 |
| AU2018291687B2 (en) | 2022-07-14 |
| RU2020102926A3 (fr) | 2021-12-21 |
| ES2996878T3 (en) | 2025-02-13 |
| EP3645526B1 (fr) | 2024-09-04 |
| JP2020525469A (ja) | 2020-08-27 |
| MX2020000135A (es) | 2020-07-22 |
| EP3645526C0 (fr) | 2024-09-04 |
| BR112019027676A2 (pt) | 2020-09-15 |
| US20210139470A1 (en) | 2021-05-13 |
| CA3068081A1 (fr) | 2019-01-03 |
| CN111032643A (zh) | 2020-04-17 |
| EP3645526A1 (fr) | 2020-05-06 |
| KR20200020888A (ko) | 2020-02-26 |
| AU2018291687A1 (en) | 2020-01-16 |
| RU2020102926A (ru) | 2021-07-27 |
| EP3645526A4 (fr) | 2020-10-28 |
| JP7261752B2 (ja) | 2023-04-20 |
| US11384075B2 (en) | 2022-07-12 |
| WO2019001419A1 (fr) | 2019-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52489A (fr) | Nouveaux composés | |
| EP3720430A4 (fr) | Composés benzocarbonyle | |
| EP3691623A4 (fr) | Composés de benzosulfonyle | |
| MA44233A (fr) | Nouveaux composés | |
| EP3836923A4 (fr) | Composés pyrrolo-dipyridine | |
| MA44050A (fr) | Nouveaux composés | |
| MA50567A (fr) | Nouveaux composés de sulfonamide carboxamide | |
| MA52948A (fr) | Composés | |
| MA49901A (fr) | Nouveaux composés de sulfonamide carboxamide | |
| MA49904A (fr) | Nouveaux composés de sulfonamide carboxamide | |
| MA56075A (fr) | Nouveaux composés de sulfonamide carboxamide | |
| EP3558322A4 (fr) | Composés benzyl-amide phosphodiamide antiviraux | |
| EP3532069A4 (fr) | Composés aryl-amide phosphodiamide antiviraux | |
| MA51669A (fr) | Composés | |
| EP3474845A4 (fr) | Composés immunomodulateurs | |
| MA42293A (fr) | Composés antibactériens | |
| MA53003A (fr) | Composés | |
| MA44020A (fr) | Composés antitumoraux | |
| MA45221A (fr) | Nouveaux composés antibactériens | |
| EP3464336A4 (fr) | Composés | |
| EP3728289A4 (fr) | Composés optimisés | |
| MA50504A (fr) | Composés antibactériens | |
| EP3405455A4 (fr) | Composés de 2-oxindole | |
| MA52946A (fr) | Composés | |
| MA53430A (fr) | Nouveaux composés |